Health Care [ 3/12 ] | Biotechnology [ 26/74 ]
NASDAQ | Common Stock
Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer.
Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial.
The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 12, 24 | -1.28 Decreased by -116.95% | -0.89 Decreased by -44.19% |
| Aug 8, 24 | -0.88 Decreased by -72.55% | -0.74 Decreased by -19.21% |
| May 9, 24 | -0.69 Decreased by -56.82% | -0.68 Decreased by -1.47% |
| Feb 27, 24 | -0.62 Decreased by -26.53% | -0.60 Decreased by -3.33% |
| Nov 14, 23 | -0.59 Decreased by -43.90% | -0.58 Decreased by -1.72% |
| Aug 10, 23 | -0.51 Decreased by -34.21% | -0.53 Increased by +3.77% |
| May 11, 23 | -0.44 Decreased by -22.22% | -0.51 Increased by +13.73% |
| Mar 16, 23 | -0.49 Decreased by -36.11% | -0.43 Decreased by -13.95% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | N/A Decreased by N/A% | -84.34 M Decreased by -150.69% | - - |
| Jun 30, 24 | 0.00 Decreased by N/A% | -57.17 M Decreased by -96.51% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -44.48 M Decreased by -120.49% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 0.00 Decreased by N/A% | -38.29 M Decreased by -93.68% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -33.65 M Decreased by -76.67% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -29.09 M Decreased by -59.84% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -20.17 M Decreased by -15.88% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Increased by +100.00% | -19.77 M Decreased by -14.36% | Decreased by N/A% Decreased by N/A% |